• Data suggests that growth differentiation factor 15 (GDF-15) has a potential association with the shortand long-term prognosis in cardiovascular diseases. There is no study evaluating the relationship of GDF-15 with the circadian pattern of hypertension (HT). Hereby, we investigated whether there is a diagnostic association between dipping and non-dipping blood pressure pattern in HT patients and found such an independent association.
Association between Growth Differentiation
Essential hypertension (EH) has been an explicit reason for cardiovascular (CV) morbidity and mortality throughout the world. The diagnosis of hypertension (HT) most of the time relies upon repeated office blood pressure (BP) measurements; however, a 24-h ambulatory BP monitoring (ABPM) yields much further data regarding the status of EH including the circadian variations in BP. Normally, a ≥10% fall in nocturnal BP is expected compared with daytime BP, which is termed as a "dipping BP" pattern. On the other hand, a non-dipping pattern is characterized by a < 10% decline in BP during nighttime [1] . Furthermore, the presence of a non-dipping BP pattern confers far greater CV risk and hence predicts worse long-term prognosis in EH patients compared with the dipping BP pattern in HT patients [2] .
Growth differentiation factor 15 (GDF-15) belongs to the transforming growth factor-β cytokine superfamily [3] . Normally, it is secreted from a congeries of cells such as endothelial cells, vascular smooth muscle cells, and macrophages in a trace amount. However, diverse pathological conditions conducive to stress response may boost its secretion from both the cardiac and non-cardiac tissues [4] . Previous studies reported elevated levels of GDF-15 in several disease conditions including acute coronary syndrome, stable coronary arterial disease, diabetes mellitus, solid cancers, EH, atrial fibrillation, and acute and chronic heart failure [4] [5] [6] [7] [8] [9] . In many of these disease conditions, GDF-15 has proved to be a predictor of prognosis more than a marker of diagnosis [4] . Accordingly, GDF-15 was also suggested as an independent predictor for allcause mortality in the general population [10] . Two previous studies showed that GDF-15 levels in EH patients with left ventricular hypertrophy (LVH) were greater compared with those of EH patients without LVH and healthy controls [11, 12] .
Although the predictive role of GDF-15 is well recognized in EH patients with LVH, its relationship with the circadian BP pattern in newly diagnosed EH patients has yet to be elucidated. Hereby, we intended to evaluate the relationship of serum GDF-15 level with the circadian BP pattern in newly diagnosed EH patients without LVH.
Subjects and Methods

Patient Population and Design
Our prospective and single-center study consecutively enrolled a total of 126 patients diagnosed with a new HT between May 2018 and October 2018. Moreover, 31 age-and sex-matched healthy subjects were recruited for a control group. The patients had not been prescribed any anti-hypertensive medication formerly. A comprehensive physical examination and a detailed inquiry about the patients' past medical history were performed. The enrolled patients were further subdivided into dipper (n = 60 patients) and non-dipper (n = 66 patients) groups on the basis of ABPM readings. BMI was calculated by dividing the weight in kilograms with the square of height in meters. We set the exclusion criteria as follows: diabetes mellitus, severe kidney failure, atherosclerotic CV disease, secondary HT, endocrine disorders, atrial fibrillation, acute infections, chronic inflammatory illnesses, left ventricular (LV) systolic dysfunction, cerebrovascular diseases, chronic obstructive pulmonary disease, smoking, alcohol or substance addiction, and being on anti-inflammatory or steroid drugs.
Twenty-Four-Hour Ambulatory BP Measurement
All the study patients with BP ≥140/90 mm Hg underwent ABPM (Bravo HR ABP SunTech Medical Inc., Morrisville, NC, USA). Measurement of BP was performed at 15-min intervals during daytime (6: 00 a.m.-10: 00 p.m.) and 30-min intervals during nighttime (10: 00 p.m.-06: 00 a.m.). Overall, the BP recordings were analyzed to obtain 24-h mean systolic BP, 24-h mean diastolic BP, daytime mean systolic BP, daytime mean diastolic BP, nighttime mean systolic BP, and nighttime mean diastolic BP in every patient. The diagnosis of HT was given to any patient with 24-h mean systolic pressure > 130 mm Hg and/or diastolic pressure > 80 mm Hg, daytime mean systolic pressure > 135 mm Hg and/or diastolic pressure > 85 mm Hg, or nighttime systolic pressure > 120 mm Hg and/or diastolic pressure > 70 mm Hg [13] . Dipping and non-dipping patterns were defined as ≥10 and < 10% BP decline during nighttime, respectively.
Echocardiography
All the study participants were examined comprehensively using a Vivid Echocardiography device (GE Vingmed Ultrasound AS, Horten, Norway). Left ventricular ejection fraction (LVEF) was determined by use of the modified Simpson's rule. Early (E) and late (A) transmitral inflow velocities, E-deceleration time (EDT), and early (E′) and late (A′) diastolic mitral annular velocities were measured as per the relevant guideline [14] . LV mass index (LVMI) was determined by use of the Devereux formula [15, 16] . LVH was defined as LVMI > 95 g/m 2 for females and > 115 g/m 2 for males according to the relevant literature [16] . EH patients complying with the term "LVH" were not included in the study.
DOI: 10.1159/000501096 Values are n (%), mean ± standard deviation, or median (25th and 75th interquartile range). BMI, body-mass index; GDF-15, growth differentiation factor-15; GFR, glomerular filtration rate; ALT, alanine aminotransferase; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; CRP, C-reactive protein; WBC, white blood cell count; Hb, hemoglobin; Plt, platelet count; ABPM, ambulatory blood pressure monitoring; SBP, systolic blood pressure; DBP, diastolic blood pressure; IVS, interventricular septum thickness; PWT, posterior left ventricular wall thickness; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; EDT, transmitral E-deceleration time; LVMI, left ventricular mass index. There is no statistically significant difference between the pairs marked with the same letter within the same line (p > 0.05). * p < 0.001, for the pair-wise comparison between the non-dipper group and healthy controls; p = 0.007, for the pair-wise comparison between the non-dipper group and the dipper group; ** p = 0.289, for the pair-wise comparison between the dipper group and healthy controls; *** p (total) < 0.001, for total comparison between all groups. 
GDF-15 and Circadian Pattern of Hypertension
Blood Tests and GDF-15 Measurement
Blood samples were drawn through venipuncture into gel-containing serum tubes between 8: 00 a.m. and 9: 00 a.m. after at least 12-h fasting and the serum was separated from the cells by centrifuging at 1,500 g for 10 min. The serum was stored at -80 ° C until the time of assay. Before analysis, the samples were thawed at room temperature. GDF-15 levels were measured using an enzymelinked immunosorbent assay (ELISA) via a commercially available assay (www.relassay.com, Gaziantep, Turkey) in accordance with the manufacturer's instructions. The limit of detection of the assay was 5.09 ng/L. The intra-and interassay coefficients of variation for GDF-15 were < 10 and < 12%, respectively.
Statistical Analysis SPSS (SPSS for Windows, Version 21.0; IBM Corp., Armonk, NY, USA) was used for the statistical analysis of the study parameters. Kolmogorov-Smirnov and Shapiro-Wilk tests were used for the normality of quantitative data. Continuous variables were expressed as mean ± standard deviation and median (25th and 75th interquartile range), while categorical variables were expressed as numbers (percentages). The study variables were compared between the groups by using the χ 2 test, one-way analysis of variance (ANOVA), and the Kruskal-Wallis H test, as per the type of variable. Comparison between groups in which a statistical difference was observed via ANOVA was performed using the Duncan multiple comparison test. Furthermore, pair-wise comparison between groups in which the Kruskal-Wallis H test revealed a statistically significant difference was performed using the Mann-Whitney U test, and the findings were assessed after Bonferroni correction. The relationship between GDF-15 and the other variables in the study population was analyzed using bivariate linear correlation analysis. Multivariate logistic regression analysis was implemented in order to determine the predictors of non-dipper HT. Finally, receiver operating characteristic (ROC) curve analysis was performed to define a diagnostic cutoff value for non-dipper HT. p < 0.05 was considered to be statistically significant.
Results
Demographic and clinical characteristics of the enrolled subjects are presented in Table 1 . The groups were similar regarding gender distribution, age, BMI, and baseline biochemical and hematological parameters. GDF-15 level was significantly greater in the non-dipper HT group, compared with the dippers and the controls (557.53 ± 91.7, 513.79 ± 62.86, and 494.44 ± 79.30 ng/L, respectively, p < 0.001) ( Table 1 ; Fig. 1) ; however, in the pair-wise comparison between the dipper HT and control groups the difference was not significant regarding GDF-15 levels (p > 0.05).
Non-dipper and dipper HT groups did not show a significant difference regarding 24-h mean systolic and diastolic BP. Furthermore, daytime mean systolic and diastolic BP were significantly greater in the dipper HT group, whereas nighttime mean systolic and diastolic BP were significantly greater in non-dippers (p < 0.001) ( Table 1) .
LV wall thicknesses, LV end-diastolic diameter, LVEF, EDT, left atrium diameter, E velocity, lateral E′ velocity, septal E/E′ ratio, lateral E/E′ ratio, and LVMI were similar among the groups (p > 0.05). Additionally, the A velocity was greater and E/A ratio was lower in the non-dippers, compared with the dippers and the controls (p < 0.001). Pair-wise comparison of the 2 HT groups displayed no significant difference regarding septal E′, septal A′, and lateral A′ velocities, all of which, however, were significantly better in the control group (Table 1) .
In bivariate linear correlation analysis, serum GDF-15 levels correlated positively with glomerular filtration rate Table 2) .
In multivariate logistic regression analysis, serum GDF-15 level (OR: 1.018; 95% CI: 1.01-1.029, p = 0.029) and nighttime diastolic BP (OR: 2.042; 95% CI: 1.487-2.804, p < 0.001) remained independently associated with the non-dipping BP pattern after adjustment for the traditional confounding factors (Table 3 ). In the ROC analysis, the optimal cutoff value for GDF-15 to predict a nondipping BP pattern with 56.7% sensitivity and 72.4% specificity was 524.6 ng/L (AUC: 0.676, 95% CI: 0.580-0.772, p < 0.05) (Fig. 2) .
Discussion
The main findings of our study can be summarized as follows: (1) serum GDF-15 levels were greater in nondippers, compared with the dippers and the healthy controls; (2) serum GDF-15 perpetuated its independent association with the non-dipping BP pattern, as evident in the multivariate logistic regression analysis; (3) serum GDF-15 level was positively correlated with septal and lateral E/E′ ratios, while negatively correlated with lateral and septal E' velocities; and (4) the appearance of a cutoff value in the ROC analysis of GDF-15 may suggest that this blood parameter is likely to be utilized as a diagnostic tool in non-dipper HT. In this regard, our study further expands the current literature on GDF-15 and HT. To our knowledge, it is the first research study where the relationship between serum GDF-15 level and non-dipping circadian pattern was evaluated, especially in HT patients without overt LVH.
GDF-15 is suggested to act as a regulatory cytokine that assumes a cardioprotective role through activation of various cellular receptors and is implicated in inflammatory and apoptotic pathways, as well as modulation of the sympathetic system [17] [18] [19] .
Recently, GDF-15 appealed more and more to pertinent researchers as a promising diagnostic and prognostic marker for cardiometabolic diseases [20] . Previous studies reported an association of GDF-15 with poor CV outcomes in a variety of clinical settings such as acute coronary syndrome, stable coronary artery diseases, and heart failure [18, 20] . In other studies, GDF-15 expression was reported to be upregulated under various stress conditions including pressure overload and sympathetic system activation [19, 21, 22] . Currently, studies evaluating the relationship between GDF-15 level and HT are scanty. In their study, Hanatani et al. [23] reported a significantly elevated serum GDF-15 level in patients with hypertensive LVH, compared with healthy controls and patients with hypertrophic cardiomyopathy. Similarly, Kou et al. [11] , in their recent study, demonstrated an elevated serum GDF-15 level in HT patients with LVH compared with those without LVH and controls. However, the GDF-15 level in their study was lower in HT patients without LVH compared with healthy controls. In another study by Xue et al. [12] , the GDF-15 level in HT patients with LVH was found to be significantly greater compared with that of HT patients without LVH. However, there was no control group in their study. Since LVH in these studies was demonstrated to have an independent and significant association with GDF-15 level in general, we specifically intended in our study to exclude HT patients with LVH in order to obviate the likely effect of LVH on serum GDF-15 levels.
The fact that the non-dipping BP pattern is associated with more extensive end-organ damage and more prevalent CV end points due to a relatively higher degree of inflammation, endothelial dysfunction and pressure overload is well recognized [2, 24, 25] . The non-dipping pattern is also associated with more impaired diastolic functions [26] . In this regard, Dinh et al. [21] suggested GDF-15 as a novel biomarker of deteriorating LV diastolic functions, regardless of the presence of well-established risk factors related with LV diastolic dysfunction such as coronary arterial disease and HT. As for the autonomic nervous system status, the nondippers were reported to possess lower parasympathetic but higher sympathetic activities compared with the dippers [27] . In accordance with this, Xu et al. [19] reported on the basis of the in vivo and in vitro assays that norepinephrine was able to stimulate GDF-15 synthesis, and upregulated GDF-15 levels in turn exerted a negative feedback on the development of norepinephrine-induced myocardial hypertrophy. Even further, they reported a positive correlation of GDF-15 with ventricular remodeling even at the prehypertrophy stage of HT, suggesting a protective function of GDF-15 against chronic sympathetic activation. However, we consider that whether GDF-15 upregulation is a true cause or a true result of a non-dipping pattern is quite intricate and needs to be elucidated with future studies.
Considering the concomitance of a greater increase in sympathetic activity, worse diastolic functions, prolonged pressure overload, and more adverse CV outcomes in the non-dipping BP pattern, it is rational to assume that GDF-15 levels are greater in non-dippers compared with dippers, even in the absence of LVH.
This study should be evaluated together with some limitations. Our study is a single-center study and comprises a relatively small population. Moreover, we did not try to correlate GDF-15 levels with some other relatively novel anti-inflammatory and endothelium-protective biomarkers. The relatively small sample size of the study may have attenuated the statistical power, especially in the ROC analysis. We also did not follow up the participating patients for future CV events.
Conclusion
Our study showed elevated serum GDF-15 levels in non-dipper HT patients compared with both dippers and healthy controls. Additionally, GDF-15 level and nighttime diastolic BP were revealed to be independently associated with a non-dipping BP pattern. Our findings suggest that GDF-15 may serve as a predictor of a nondipping circadian pattern in patients with a new EH. However, future multicenter studies with larger populations are needed to confirm our findings.
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